Pediatric Cannabinoid Prescribing: Safeguards and Consent

Narrow indications, specialist oversight, and documented consent define responsible pediatric use.

Clinical Context

Cannabinoid evidence is moving from case series toward controlled trials. Reading that literature well avoids both premature enthusiasm and unwarranted dismissal.

What the Data Show

Reported effects depend heavily on route of administration, THC:CBD ratio, and patient profile. Comparing studies without adjusting for these variables produces fragile conclusions.

Applying It in Clinic

Start low, titrate slowly, and document response remains the most defensible practice. Structured dose-and-effect records turn clinical experience into usable data.

Bottom Line

Responsible prescribing rests on standardized product, realistic expectations, and systematic follow-up.